Gemcitabine Hydrochloride

CHEMBL1637 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

299.7 g/mol

LogP

—

Phase

4

This hydrochloride salt form of gemcitabine is an intravenous chemotherapy drug that disrupts DNA replication in rapidly dividing cancer cells. It is a cornerstone treatment for pancreatic cancer and is also used in lung, bladder, breast, and other solid tumors.

分子量

299.6600 g/mol

TPSA

108.00 Å²

治療領域

Oncology Cardiovascular Disease Infectious Disease Neurology Psychiatry Endocrinology Respiratory Disease Gastroenterology Rheumatology Dermatology Nephrology Hematology Pain Management Ophthalmology Urology Immunology Obstetrics & Gynecology Anesthesiology Hepatology Transplant Medicine Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Malaria Heart Failure Atrial Fibrillation Stroke Deep Vein Thrombosis / Pulmonary Embolism Hyperlipidemia Obesity Gastroesophageal Reflux Disease Inflammatory Bowel Disease Osteoporosis Psoriasis Atopic Dermatitis Systemic Lupus Erythematosus Multiple Sclerosis Gout Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Prostate Cancer Colorectal Cancer Leukemia Lymphoma Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Benign Prostatic Hyperplasia Glaucoma Age-Related Macular Degeneration

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1

InChI

InChI=1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1

Molecular Formula

C9H12ClF2N3O4

HBD / HBA

4 / 6

回転可能結合数

2

重原子数

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This hydrochloride salt form of gemcitabine is an intravenous chemotherapy drug that disrupts DNA replication in rapidly dividing cancer cells. It is a cornerstone treatment for pancreatic cancer and is also used in lung, bladder, breast, and other solid tumors.

Yes, Gemcitabine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1637. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 60749. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Gemcitabine Hydrochloride PillFYIで

構造

クイックデータ

分子式: C9H12ClF2N3O4
同義語: 1

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.